Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v2-FR Version v1-EN
Language French English
Date Updated 2019-06-10 2019-06-10
Drug Identification Number 01927604 01927604
Brand name MYOCHRYSINE MYOCHRYSINE
Common or Proper name Myochrysine 50mg Myochrysine 50mg
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients GOLD SODIUM THIOMALATE GOLD SODIUM THIOMALATE
Strength(s) 50MG 50MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 5 ampoules 5 ampoules
ATC code M01CB M01CB
ATC description SPECIFIC ANTIRHEUMATIC AGENTS SPECIFIC ANTIRHEUMATIC AGENTS
Reason for discontinuation Other (Please describe in comments) Other (Please describe in comments)
Anticipated discontinuation date
Actual discontinuation date 2019-06-04 2019-06-04
Remaining supply date 2017-12-01 2017-12-01
Discontinuation status Discontinued Discontinued
Discontinuation decision reversal no no
Information on remaining supply
Company comments The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally.
Health Canada comments